Zinnia P Parra-Guillen

List of Publications by Year
in descending order

34 papers	452 citations	687363 13 h-index	752698 20 g-index
34 all docs	34 docs citations	34 times ranked	829 citing authors

#	Article	IF	Citations
1	Relevance of primary lesion location, tumour heterogeneity and genetic mutation demonstrated through tumour growth inhibition and overall survival modelling in metastatic colorectal cancer. British Journal of Clinical Pharmacology, 2022, 88, 166-177.	2.4	7
2	Mechanistic modelling of enzymeâ€restoration effects of new recombinant liverâ€targeted proteins in acute intermittent porphyria. British Journal of Pharmacology, 2022, , .	5.4	1
3	A quantitative systems pharmacology model for acute viral hepatitis B. Computational and Structural Biotechnology Journal, 2021, 19, 4997-5007.	4.1	1
4	Mechanistic Modeling of a Novel Oncolytic Virus, V937, to Describe Viral Kinetic and Dynamic Processes Following Intratumoral and Intravenous Administration. Frontiers in Pharmacology, 2021, 12, 705443.	3.5	11
5	Semi-Mechanistic Model for the Antitumor Response of a Combination Cocktail of Immuno-Modulators in Non-Inflamed (Cold) Tumors. Cancers, 2021, 13, 5049.	3.7	2
6	Modelâ€Informed Dose Selection for Xentuzumab, a Dual Insulinâ€Like Growth Factorâ€I/IIâ€”Neutralizing Antibody. Clinical Pharmacology and Therapeutics, 2020, 107, 597-606.	4.7	6
7	Machine Learning Analysis of Individual Tumor Lesions in Four Metastatic Colorectal Cancer Clinical Studies: Linking Tumor Heterogeneity to Overall Survival. AAPS Journal, 2020, 22, 58.	4.4	14
8	Disease pharmacokineticâ€“pharmacodynamic modelling in acute intermittent porphyria to support the development of mRNA â€based therapies. British Journal of Pharmacology, 2020, 177, 3168-3182.	5.4	8
9	A Quantitative Systems Pharmacology Model for the Key Interleukins Involved in Crohn's Disease. Journal of Pharmacology and Experimental Therapeutics, 2020, 372, 299-307.	2.5	9
10	Pharmacokinetic/Pharmacodynamic Evaluation of Hydrocortisone Therapy in Pediatric Patients with Congenital Adrenal Hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1729-e1740.	3.6	18
11	Paediatric population pharmacokinetic modelling to assess hydrocortisone replacement dosing regimens in young children. European Journal of Endocrinology, 2020, 183, 357-368.	3.7	10
12	Response to â€˜Hydrocortisone suspension formulations are not necessarily the same in the treatment of children with congenital adrenal hyperplasiaâ€™. European Journal of Endocrinology, 2020, 183, L29-L30.	3.7	0
13	Immune network for viral hepatitis B: Topological representation. European Journal of Pharmaceutical Sciences, 2019, 136, 104939.	4.0	1
14	The circadian rhythm of corticosteroidâ€binding globulin has little impact on cortisol exposure after hydrocortisone dosing. Clinical Endocrinology, 2019, 91, 33-40.	2.4	9
15	Computational disease model of phenobarbital-induced acute attacks in an acute intermittent porphyria mouse model. Molecular Genetics and Metabolism, 2019, 128, 367-375.	1.1	2
16	Systematic Modeling and Design Evaluation of Unperturbed Tumor Dynamics in Xenografts. Journal of Pharmacology and Experimental Therapeutics, 2018, 366, 96-104.	2.5	9
17	The Long Neglected Player: Modeling Tumor Uptake to Guide Optimal Dosing. Clinical Cancer Research, 2018, 24, 3236-3238.	7.0	6
18	Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients. Clinical Pharmacokinetics, 2018, 57, 229-242.	3.5	21

#	Article	IF	Citations
19	Predicting Cortisol Exposure from Paediatric Hydrocortisone Formulation Using a Semi-Mechanistic Pharmacokinetic Model Established in Healthy Adults. Clinical Pharmacokinetics, 2018, 57, 515-527.	3.5	15
20	Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Nonâ€smallâ€Cell Lung Cancer Receiving Erlotinib Treatment. Basic and Clinical Pharmacology and Toxicology, 2017, 121, 309-315.	2.5	17
21	Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia. Journal of Pharmacology and Experimental Therapeutics, 2017, 362, 347-358.	2.5	27
22	Model Description Language (MDL): A Standard for Modeling and Simulation. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 647-650.	2.5	15
23	Making use of modeling and simulations: Towards individualized tamoxifen therapy inÂbreast cancer. International Journal of Clinical Pharmacology and Therapeutics, 2017, 55, 690-691.	0.6	1
24	Utilising the EGFR interactome to identify mechanisms of drug resistance in non-small cell lung cancer â€“ Proof of concept towards a systems pharmacology approach. European Journal of Pharmaceutical Sciences, 2016, 94, 20-32.	4.0	22
25	Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development. CPT: Pharmacometrics and Systems Pharmacology, 2015, 4, 316-319.	2.5	37
26	Population Pharmacokinetic Modelling of Irosustat in Postmenopausal Women with Oestrogen-Receptor Positive Breast Cancer Incorporating Non-Linear Red Blood Cell Uptake. Pharmaceutical Research, 2015, 32, 1493-1504.	3.5	5
27	Pharmacokinetics and Pharmacokineticâ€“Pharmacodynamic Relationships of Monoclonal Antibodies in Children. Clinical Pharmacokinetics, 2015, 54, 35-80.	3.5	34
28	Review on modeling anti-antibody responses to monoclonal antibodies. Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41, 523-536.	1.8	39
29	Mathematical Model Approach to Describe Tumour Response in Mice After Vaccine Administration and its Applicability to Immune-Stimulatory Cytokine-Based Strategies. AAPS Journal, 2013, 15, 797-807.	4.4	24
30	Target-Mediated Disposition Model Describing the Dynamics of IL12 and IFNÎ³ after Administration of a Mifepristone-Inducible Adenoviral Vector for IL-12 Expression in Mice. AAPS Journal, 2013, 15, 183-194.	4.4	4
31	Modeling Tumor Response after Combined Administration of Different Immune-Stimulatory Agents. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 432-442.	2.5	19
32	The Fusion Protein of IFN-Î± and Apolipoprotein A-I Crosses the Bloodâ€“Brain Barrier by a Saturable Transport Mechanism. Journal of Immunology, 2012, 188, 3988-3992.	0.8	16
33	Kinetic and Dynamic Computational Model-Based Characterization of New Proteins in Mice: Application to Interferon Alpha Linked to Apolipoprotein A-I. PLoS ONE, 2012, 7, e42100.	2.5	2
34	Gene Therapy: A Pharmacokinetic/Pharmacodynamic Modelling Overview. Pharmaceutical Research, 2010, 27, 1487-1497.	3.5	40